Your browser doesn't support javascript.
loading
An exploratory analysis of the factors leading to delays in cancer drug reimbursement in the European Union: the trastuzumab case.
Ades, Felipe; Senterre, Chistelle; Zardavas, Dimitrios; de Azambuja, Evandro; Popescu, Razvan; Parent, Florence; Piccart, Martine.
Affiliation
  • Ades F; Department of Medical Oncology, Institut Jules Bordet, Université Libre de Bruxelles, Boulevard de Waterloo 121 (7th Floor), 1000 Brussels, Belgium.
  • Senterre C; Research Center of Epidemiology, Biostatistics and Clinical Research, School of Public Health, Université Libre de Bruxelles, Campus Erasme - CP598, Route de Lennik 808, 1070 Brussels, Belgium.
  • Zardavas D; Breast International Group Headquarters (BIG-aisbl), Brussels, Belgium.
  • de Azambuja E; Department of Medical Oncology, Institut Jules Bordet, Université Libre de Bruxelles, Boulevard de Waterloo 121 (7th Floor), 1000 Brussels, Belgium.
  • Popescu R; Department of Medical Oncology, Hirslanden Clinic Aarau, Schänisweg, 5001 Aarau, Switzerland.
  • Parent F; Research Center of Social Approaches of Health, School of Public Health, Université Libre de Bruxelles, Campus Erasme - CP 596, Route de Lennik, 808, 1070 Brussels, Belgium.
  • Piccart M; Department of Medical Oncology, Institut Jules Bordet, Université Libre de Bruxelles, Boulevard de Waterloo 121 (7th Floor), 1000 Brussels, Belgium. Electronic address: martine.piccart@bordet.be.
Eur J Cancer ; 50(18): 3089-97, 2014 Dec.
Article in En | MEDLINE | ID: mdl-25446375
Subject(s)
Key words
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Reimbursement Mechanisms / Breast Neoplasms / Antibodies, Monoclonal, Humanized / Antineoplastic Agents Type of study: Guideline / Prognostic_studies Limits: Female / Humans Language: En Journal: Eur J Cancer Year: 2014 Type: Article Affiliation country: Belgium
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Reimbursement Mechanisms / Breast Neoplasms / Antibodies, Monoclonal, Humanized / Antineoplastic Agents Type of study: Guideline / Prognostic_studies Limits: Female / Humans Language: En Journal: Eur J Cancer Year: 2014 Type: Article Affiliation country: Belgium